Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626845 · ClinicalTrials.gov registry record · Phase 4
Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT02626845 is a Phase 4 study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 3 participants.
The verdict
NCT02626845, a Phase 4 study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase IV, single-center, randomized, placebo-controlled pilot study that will evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with active otolaryngologic disease.
Interventions
- OTHER Placebo
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626845
The ClinicalTrials.gov registry entry for NCT02626845 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02626845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02626845 about?
NCT02626845 is a clinical study titled "Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis". This is a phase IV, single-center, randomized, placebo-controlled pilot study that will evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with active otolaryngologic disease.
What is the current status of trial NCT02626845?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2015-12. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02626845?
The interventions under investigation include: Placebo (OTHER), Rituximab (DRUG).
Who is sponsoring clinical trial NCT02626845?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.